| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
43,700,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Prelude Therapeutics is a clinical-stage oncology company built on a foundation of drug discovery to deliver precision cancer medicines to underserved patients. Co.'s primary candidates are designed to be oral, potent and selective inhibitors of protein arginine methyltransferase 5 (PRMT5). PRT811, Co.'s second clinical candidate, is a PRMT5 inhibitor that it has optimized for high brain exposure. PRT1419, Co.'s third clinical candidate, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1. PRT2527, Co.'s fourth clinical candidate, is designed to be a potent and selective Cyclin-dependent kinase 9 inhibitor.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
1,760,286 |
1,799,474 |
| Total Buy Value |
$0 |
$0 |
$10,116,973 |
$10,305,319 |
| Total People Bought |
0 |
0 |
5 |
5 |
| Total Buy Transactions |
0 |
0 |
7 |
10 |
| Total Shares Sold |
0 |
0 |
0 |
13,280 |
| Total Sell Value |
$0 |
$0 |
$0 |
$81,274 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
1 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Scherle Peggy |
Chief Scientific Officer |
• – – |
2021-04-07 |
4 |
AS |
$39.02 |
$604,144 |
D/D |
(15,370) |
172,920 |
|
- |
|
| Scherle Peggy |
Chief Scientific Officer |
• – – |
2021-04-07 |
4 |
A |
$1.43 |
$21,979 |
D/D |
15,370 |
188,290 |
|
- |
|
| Morosini Deborah |
EVP, Chief of Clinical Affairs |
• – – |
2021-04-07 |
4 |
AS |
$40.04 |
$40,043 |
D/D |
(1,000) |
444 |
|
- |
|
| Morosini Deborah |
EVP, Chief of Clinical Affairs |
• – – |
2021-04-07 |
4 |
OE |
$1.89 |
$1,890 |
D/D |
1,000 |
1,444 |
|
- |
|
| Baker Julian |
Director |
– • • |
2021-01-27 |
4 |
OE |
$12.85 |
$133,332 |
I/I |
10,376 |
9,252,951 |
|
- |
|
| Baker Julian |
Director |
– • • |
2020-09-29 |
4 |
B |
$19.00 |
$29,999,993 |
I/I |
1,578,947 |
9,247,763 |
2.25 |
- |
|
| Baker Julian |
Director |
– • • |
2020-09-29 |
4 |
A |
$0.00 |
$0 |
I/I |
8,332,778 |
7,773,444 |
|
- |
|
| Bonita David P |
Director |
– • • |
2020-09-29 |
4 |
A |
$0.00 |
$0 |
I/I |
8,332,779 |
9,250,191 |
|
- |
|
| Friedman Paul A |
Director |
– • – |
2020-09-29 |
4 |
A |
$0.00 |
$0 |
D/D |
448,370 |
500,098 |
|
- |
|
| Vaddi Krishna |
President, CEO |
• • – |
2020-09-29 |
4 |
A |
$0.00 |
$0 |
I/I |
167,229 |
551,774 |
|
- |
|
| Orbimed Capital Llc |
Director |
– • • |
2020-09-29 |
4 |
A |
$0.00 |
$0 |
I/I |
8,332,779 |
9,250,191 |
|
- |
|
| Combs Andrew |
EVP, Head of Chemistry |
• – – |
2020-09-29 |
4 |
B |
$19.00 |
$19,000 |
D/D |
1,000 |
260,380 |
2.74 |
- |
|
| Dier Mardi |
Director |
– • – |
2020-09-29 |
4 |
B |
$19.00 |
$190,000 |
D/D |
10,000 |
10,000 |
2.39 |
- |
|
| Morosini Deborah |
EVP, Chief of Clinical Affairs |
• – – |
2020-09-29 |
4 |
B |
$19.00 |
$8,436 |
D/D |
444 |
444 |
2.74 |
- |
|
| Pierce Christopher |
EVP and Chief of Business Oper |
• – – |
2020-09-29 |
4 |
B |
$19.00 |
$71,250 |
D/D |
3,750 |
3,750 |
2.74 |
- |
|
| Bonita David P |
Director |
– • • |
2020-09-25 |
4 |
B |
$19.00 |
$23,499,200 |
I/I |
1,236,800 |
917,412 |
2.25 |
- |
|
| Orbimed Capital Llc |
Director |
– • • |
2020-09-25 |
4 |
B |
$19.00 |
$23,499,200 |
I/I |
1,236,800 |
917,412 |
2.25 |
- |
|
| Scherle Peggy |
Chief Scientific OfficerOffice |
• – – |
2020-09-24 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
172,920 |
|
- |
|
| Friedman Paul A |
Director |
– • – |
2020-09-24 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
51,728 |
|
- |
|
| Baker Julian |
Director |
– • • |
2020-09-24 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
206,911 |
|
- |
|
| Combs Andrew |
EVP, Head of ChemistryOfficer |
• – – |
2020-09-24 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
259,380 |
|
- |
|
| Orbimed Capital Gp Vi Llc |
Director |
– • • |
2020-09-24 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
206,912 |
|
- |
|
| Bonita David P |
Director |
– • • |
2020-09-24 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
206,912 |
|
- |
|
| Vaddi Krishna |
President, CEOOfficer |
• • – |
2020-09-24 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,461,453 |
|
- |
|
| Vaddi Krishna |
President, CEOOfficer |
• • – |
2020-09-24 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,045,519 |
|
- |
|
100 Records found
|
|
Page 4 of 4 |
|
|
